EP Patent

EP3700531A1 — Dosage regimen of paliperidone palmitate extended-release injectable suspension

Assigned to Geneora Pharma Shijiazhuang Co Ltd · Expires 2020-09-02 · 6y expired

What this patent protects

Provided herein are simplified dosing regimens for administering paliperidone palmitate to a patient in need of treatment of schizophrenia or schizoaffective disorders.

USPTO Abstract

Provided herein are simplified dosing regimens for administering paliperidone palmitate to a patient in need of treatment of schizophrenia or schizoaffective disorders.

Drugs covered by this patent

Patent Metadata

Patent number
EP3700531A1
Jurisdiction
EP
Classification
—
Expires
2020-09-02
Drug substance claim
No
Drug product claim
No
Assignee
Geneora Pharma Shijiazhuang Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.